References
- Beauclair L., Vinogradov S., Kiney S. J., Csemansky J. G., Hollister L. E. An adjunctive role for ascorbic acid in the treatment of schizophrenia. Journal of Clinical Psychopharmacology 1987; 7: 282–283
- Brown W. A., Herz L. K. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophrenia Bulletin 1989; 15: 123–129
- Cadet J. L. The potential use of vitamin E and selenium in parkinsonism. Medical Hypotheses 1986; 20: 87–94
- Crow T. J., Deakin J. F. W., Longden A. The nucleus accumbens-possible site of antipsychotic action of neuroleptics. Psychological Medicine 1977; 7: 213–221
- Giannini A. J., Loiselle R. H., Di Marzio L. R., Giannini J. D. Augmentation of haloperidol by ascorbic acid in phencyclidine intoxication. American Journal of Psychiatry 1987; 144: 1207–1209
- Heikkila K. E., Manzino L., Cabbat F. S., Hanly J. G. Ascorbic acid and the binding of DA agonists to neostriatal membrane preparations. Neuropharmacology 1983; 22: 135–137
- Herjanic M., Moss-Herjanic B. L. Ascorbic acid test in psychiatric patients. Journal of Schizophrenia 1967; 1: 257–260
- Kanofsky J. D., Kay S. R., Lindenmayer J. P., Seifter E. Ascorbic acid and dopamine activity. American Journal of Psychiatry 1988; 145: 904–905
- Kanofsky J. D., Kay S. R., Lindenmayer J. P., Seifter E. Ascorbate: An adjunctive treatment for schizophrenia. Journal of the American College of Nutrition 1989b; 8: 425
- Kanofsky J. D., Kay S. R., Lindenmayer J. P., Seifter E. Ascorbate reverses neurolepticinduced amenorrhea. Journal of the American College of Nutrition 1989a; 8: 425
- Medford I. N., Oke A. F., Adams R. N. Regional distribution of ascorbate in human brain. Brain Research 1981; 212: 223–226
- Milby K., Oke A. F., Adams R. N. Detailed mapping of ascorbate distribution in rat brain. Neuroscience Letters 1982; 28: 15–20
- Milner G. Ascorbic acid in chronic psychiatric patients-a controlled trial. British Journal of Psychiatry 1963; 109: 294–299
- Pauling L. On the orthomolecular environment of the mind: Orthomolecular theory. American Journal of Psychiatry 1974; 131: 1251–1257
- Phebus L. A., Roush M. E., Clemens J. A. Effect of direct and indirect dopamine agonists on brain extracellular ascorbate levels in the striatum and nucleus accumbens of awake rats. Life Sciences 1990; 47: 1317–1323
- Rebec G. V., Centore J. M., White L. K., Alloway K. D. Ascorbic acid and the behavioral response to baloperidol: implication for the action of antipsychotic drugs. Science 1984; 227: 438–440
- Reilly D. K., Hershey L., Rivera-Calimim L., Shoulson I. On-Off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Experimental therapeutics of movement disorders, S. Fahn, D. B. Calne, I. Shoulson. Raven Press, New York 1983; 51–60
- Stevens J. R. Schizophrenia and dopamine regulation in the mesolimbic system. Trends in Neuroscience 1979; 2: 102–105
- Suboticanec K., Folnegovic-Smale V., Turcin R., Mestrovic B., Buzina R. Plasma levels and urinary vitamin C excretion in schizophrenic patients. Human Nutrition: clinical nutrition 1986; 40C: 421–428
- Thomas T. N., Zemp J. W. Inhibition of dopamine sensitive adenylate cyclase from rat brain striatal homogenates by ascorbic acid. Journal of Neurochemistry 1977; 28: 663–665
- Tolbert L. C., Thomas T. N., Middaugh L. D., Zemp J. W. Effect of ascorbic acid on neurochemical, behavioral, and physiological symptoms mediated by catecholamines. Life Sciences 1979; 25: 2189–2195
- Vanderkamp H. A biochemical abnormality in schizophrenia involving ascorbic acid. International Journal of Neuropsychiatry 1966; 2: 204–206